At Kinesys Consulting our highly experienced Principals and Expert Panel provide support and solutions for strategic development, regulatory and technical challenges faced by pharmaceutical and biotechnology companies. The Principals – Gerry McGettigan, Emma Holmes, Martin Jordan and Elaine Murphy – have all held senior posts in Pharma, Biotech and Medtech companies, in regulatory affairs, clinical development and business development. We have all previously set up and run successful consultancy organizations. Our contacts with regulatory authorities, industry leaders and venture capital firms are second to none. How we can help you   Therapeutic and Development Experience Our expertise extends to most drug therapeutic areas. The Principals and Expert Panel have all worked on the development and registration of innovative and important new therapies in the areas of, for example, oncology, metabolic diseases, CNS and anti-infectives. We have the knowledge and experience to add value both to extensive development programmes for broad disease areas and to accelerated and limited programmes for orphan or niche indications often representing high unmet medical needs.   Types of products Our expertise extends to NCEs, re-profiled products, recombinant therapies, cell therapies and stem cell agents. Our clients include some of the largest Pharma and Biotech companies as well as innovative start up firms. We have also worked on combination products involving drugs and devices and complex tissue engineered products. We typically conduct market analyses and provide pricing & reimbursement strategies and advice in Europe for our clients. Expert Panel The company’s Expert Panel is composed of senior academics, experienced industrialists and successful entrepreneurs. The Expert Panel has been selected to bring together difficult-to-find, specialist knowledge and expertise from respected public figures. Our Experts and Principals work together, often representing clients and supporting their positions in negotiations with prospective business partners and with EMA, FDA and other regulatory authorities. This approach frequently makes the difference in securing the optimum outcome for our clients.